Cel-Sci Corporation (CVM) Stock Price

CVMStock

$1.56−83.24%52W

Market Cap$27.44M

P/E—

PEG Ratio1.12

Div yield—

Beta0.68

CVM Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-77.87%

Price vs S&P 500 (4W)23.26%

PEG Ratio1.12

VGM Score35.25

Book Value / Share (Quarterly)$0.81

P/TBV (Annual)4.64x

Cash Flow / Share (Quarterly)$-1.96

Price vs S&P 500 (YTD)-83.16%

Net Profit Margin (TTM)-5445.76%

EPS (TTM)$-3.58

10-Day Avg Trading Volume0.16M

EPS Excl Extra (TTM)$-3.58

EPS (Annual)$-21.72

ROI (Annual)-129.11%

Net Profit Margin (5Y Avg)-8345.71%

Cash / Share (Quarterly)$0.22

ROA (Last FY)-105.46%

EBITD / Share (TTM)$-2.68

ROE (5Y Avg)-201.32%

Operating Margin (TTM)-5218.40%

Cash Flow / Share (Annual)$-2.14

P/B Ratio3.71x

P/B Ratio (Quarterly)3.95x

EV / Revenue (TTM)54.52x

Net Interest Coverage (TTM)-46.67x

ROA (TTM)-101.92%

EPS Incl Extra (Annual)$-21.72

Current Ratio (Annual)2.26x

Quick Ratio (Quarterly)0.39x

3-Month Avg Trading Volume0.44M

52-Week Price Return-83.24%

Tangible BV / Share (Quarterly)$0.80

P/S Ratio (Annual)45.64x

Asset Turnover (Annual)0.01x

52-Week High$12.68

Operating Margin (5Y Avg)-10456.68%

EPS Excl Extra (Annual)$-21.72

CapEx CAGR (5Y)-57.33%

Tangible BV CAGR (5Y)-3.99%

26-Week Price Return-65.94%

Quick Ratio (Annual)2.14x

13-Week Price Return5.41%

Total Debt / Equity (Annual)0.50x

Current Ratio (Quarterly)0.60x

Enterprise Value$30.46M

Asset Turnover (TTM)0.01x

Book Value / Share Growth (5Y)31.34%

Pretax Margin (Annual)-5415.68%

Cash / Share (Annual)$1.37

3-Month Return Std Dev94.31%

ROE (Last FY)-243.62%

Net Interest Coverage (Annual)-43.88x

EPS Basic Excl Extra (Annual)$-21.72

Receivables Turnover (TTM)0.00x

Total Debt / Equity (Quarterly)1.00x

EPS Incl Extra (TTM)$-3.58

Receivables Turnover (Annual)0.00x

ROI (TTM)-126.66%

P/S Ratio (TTM)45.64x

Pretax Margin (5Y Avg)-8345.71%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$1.98

Price vs S&P 500 (52W)-101.80%

Year-to-Date Return-70.34%

5-Day Price Return13.04%

EPS Normalized (Annual)$-21.72

ROA (5Y Avg)-76.16%

Net Profit Margin (Annual)-5415.68%

Month-to-Date Return34.48%

Cash Flow / Share (TTM)$-0.67

EBITD / Share (Annual)$-18.56

Operating Margin (Annual)-5188.32%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-94.73%

LT Debt / Equity (Quarterly)0.10x

EPS Basic Excl Extra (TTM)$-3.58

P/TBV (Quarterly)3.99x

P/B Ratio (Annual)4.61x

Pretax Margin (TTM)-5445.76%

Book Value / Share (Annual)$1.99

Price vs S&P 500 (13W)3.45%

Beta0.68x

Revenue / Share (TTM)$0.00

ROE (TTM)-221.50%

52-Week Low$0.89

vGradeD

mGradeC

vgmGradeD

CVM Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.00

Industry Peers — Biological Products(183)

Symbol	Value Score	Growth Score	Momentum Score	Price
CVMCel-Sci Corporation	D	—	C	$1.56
AMGNAmgen Inc	C	C	B	$432.42
GILDGilead Sciences Inc	C	B	B	$145.68
ARGXargenx SE American Depositary Shares	D	A	B	$1023.21
MRNAModerna, Inc. Common Stock	D	C	A	$137.99
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$207.88
BIIBBiogen Inc. Common Stock	C	D	B	$218.50
BNTXBioNTech SE American Depositary Share	C	C	C	$102.08
NBIXNeurocrine Biosciences Inc	C	B	C	$154.06
EXELExelixis Inc	C	B	B	$54.45
HALOHalozyme Therapeutics, Inc.	C	B	B	$105.35
TECHBio-Techne Corp.	D	C	B	$72.35
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	$351.46
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	$134.97
RGENRepligen Corp	D	C	B	$176.27
KYMRKymera Therapeutics, Inc. Common Stock	D	B	B	$118.15
PCVXVaxcyte, Inc. Common Stock	—	—	B	$59.84
QGENQIAGEN N.V.	C	C	B	$43.11
TWSTTwist Bioscience Corporation Common Stock	D	B	A	$141.38
IBRXImmunityBio, Inc. Common Stock	F	A	B	$8.05
IMVTImmunovant, Inc. Common Stock	—	—	B	$41.20
SRRKScholar Rock Holding Corporation Common Stock	F	—	B	$57.80
CGONCG Oncology, Inc. Common stock	F	A	B	$74.34
CRSPCRISPR Therapeutics AG	D	B	C	$57.72
RLAYRelay Therapeutics, Inc. Common Stock	F	D	B	$18.77
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	A	$25.19
DNLIDenali Therapeutics Inc. Common Stock	F	—	B	$24.00
IOVAIovance Biotherapeutics, Inc. Common Stock	C	B	A	$8.01
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	$71.76
BEAMBeam Therapeutics Inc. Common Stock	C	B	B	$29.32
BCRXBioCryst Pharmaceuticals Inc	B	A	B	$9.82
KODKodiak Sciences Inc Common Stock	—	—	B	$37.72
MESOMesoblast Limited American Depositary Shares	D	B	B	$17.44
VCELVericel Corporation	D	B	B	$40.95
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	B	$44.84
ADMAADMA Biologics, Inc.	C	C	C	$9.34
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	$36.62
TSHATaysha Gene Therapies, Inc. Common Stock	F	B	B	$5.77
VIRVir Biotechnology, Inc. Common Stock	B	B	B	$10.83
INBXInhibrx Biosciences, Inc. Common Stock	D	C	A	$123.41
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	$3.34
ALVOAlvotech Ordinary Shares	C	D	C	$4.95
NVAXNovavax Inc	B	D	C	$9.26
MAZEMaze Therapeutics, Inc. Common Stock	—	—	C	$27.44
SLBTSL Science Holding Limited Ordinary Shares	—	—	C	$2.70
REPLReplimune Group, Inc.	—	—	A	$15.50
IMTXImmatics N.V. Ordinary Shares	C	D	C	$9.45
VORVor Biopharma Inc. Common Stock	—	—	B	$22.65
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	A	$21.70
MGTXMeiraGTx Holdings plc Ordinary Shares	D	C	B	$13.82
SANASana Biotechnology, Inc. Common Stock	—	—	B	$3.93

About Cel-Sci Corporation

CEL-SCI Corp is a late-stage biotechnology company developing immunotherapies designed to leverage the immune system against cancer and autoimmune diseases. Its lead program, Multikine, is in Phase 3 clinical trials for head and neck cancer. The company is also advancing its LEAPS technology platform for potential treatment of rheumatoid arthritis.